• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cardiovasc Res . Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, E

tetano

Editor, Senior Moderator
Cardiovasc Res


. 2021 Sep 16;cvab298.
doi: 10.1093/cvr/cvab298. Online ahead of print.
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)


Edina Cenko[SUP] 1 [/SUP], Lina Badimon[SUP] 2 [/SUP], Raffaele Bugiardini[SUP] 1 [/SUP], Marc J Claeys[SUP] 3 [/SUP], Giuseppe De Luca[SUP] 4 [/SUP], Cor de Wit[SUP] 5 6 [/SUP], Geneviève Derumeaux[SUP] 7 8 9 [/SUP], Maria Dorobantu[SUP] 10 [/SUP], Dirk J Duncker[SUP] 11 [/SUP], Etto C Eringa[SUP] 12 13 [/SUP], Diana A Gorog[SUP] 14 15 [/SUP], Christian Hassager[SUP] 16 [/SUP], Frank R Heinzel[SUP] 17 18 [/SUP], Kurt Huber[SUP] 19 20 [/SUP], Olivia Manfrini[SUP] 1 [/SUP], Davor Milicic[SUP] 21 [/SUP], Evangelos Oikonomou[SUP] 22 [/SUP], Teresa Padro[SUP] 2 [/SUP], Danijela Trifunovic-Zamaklar[SUP] 23 24 [/SUP], Zorana Vasiljevic-Pokrajcic[SUP] 24 [/SUP], Marija Vavlukis[SUP] 25 [/SUP], Gemma Vilahur[SUP] 2 [/SUP], Dimitris Tousoulis[SUP] 22 [/SUP]



Affiliations

Abstract

The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between SARS-CoV-2 and ACE2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as "post-acute COVID-19" may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.

Keywords: COVID-19; SARS-CoV-2; cardiovascular disease; cytokines; endothelial dysfunction; infection; inflammation; microcirculation; myocardial injury; post-acute COVID-19; thrombosis.
 
Back
Top Bottom